Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrenibotulinumtoxinE and OnabotulinumtoxinA for Upper Facial Lines
NCT07871513Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of trenibotulinumtoxinE in glabellar lines, sponsored by AbbVie Inc.. Started Oct 2026; status: recruiting.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT07871513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871513.